Literature DB >> 24998605

The inpatient costs and hospital service use associated with invasive meningococcal disease in South Australian children.

Bing Wang1, Hossein Haji Ali Afzali2, Helen Marshall3.   

Abstract

BACKGROUND: Invasive meningococcal disease (IMD) remains a serious public health concern due to a sustained high case fatality rate and morbidity in survivors. This study aimed to estimate the hospital service costs associated with IMD and variables associated with the highest costs in Australian children admitted to a tertiary paediatric hospital.
METHODS: Clinical details were obtained from medical records and associated inpatient costs were collected and inflated to 2011 Australian dollars using the medical and hospital services component of the Australian Consumer Price Index. Both unadjusted and adjusted analyses were undertaken. Multivariate regression models were used to adjust for potential covariates and determine independent predictors of high costs and increased length of hospital stay.
RESULTS: Of 109 children hospitalised with IMD between May 2000 and April 2011, the majority were caused by serogroup B (70.6%). Presence of sequelae, serogroup B infection, male gender, infants less than one year of age, and previous medical diagnosis were associated with higher inpatient costs and length of stay (LOS) in hospital (p<0.001) during the acute admissions. Children diagnosed with septicaemia had a longer predicted LOS (p=0.033) during the acute admissions compared to those diagnosed with meningitis alone or meningitis with septicaemia. Serogroup B cases incurred a significantly higher risk of IMD related readmissions (IRR: 21.1, p=0.008) for patients with sequelae. Serogroup B infection, male gender, diagnosis of septicaemia, infants less than one year of age, and no previous medical diagnosis were more likely to have higher inpatient costs and LOS during the IMD related readmissions for patients with sequelae (p<0.05).
CONCLUSION: Although IMD is uncommon, the disease severity and associated long-term sequelae result in high health care costs, which should be considered in meningococcal B vaccine funding considerations.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Inpatient costs; Length of admission; Meningococcal B vaccines; Meningococcal disease

Mesh:

Year:  2014        PMID: 24998605     DOI: 10.1016/j.vaccine.2014.05.069

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

1.  Cost Effectiveness of Meningococcal Serogroup B Vaccination in College-Aged Young Adults.

Authors:  Ira L Leeds; Vasanthkumar Namasivayam; Assanatou Bamogo; Prithvi Sankhla; Winter M Thayer
Journal:  Am J Prev Med       Date:  2018-12-17       Impact factor: 5.043

2.  Costs of Invasive Meningococcal Disease: A Global Systematic Review.

Authors:  Bing Wang; Renee Santoreneos; Hossein Afzali; Lynne Giles; Helen Marshall
Journal:  Pharmacoeconomics       Date:  2018-10       Impact factor: 4.981

3.  Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysis.

Authors:  Roberto Gasparini; Paolo Landa; Daniela Amicizia; Giancarlo Icardi; Walter Ricciardi; Chiara de Waure; Elena Tanfani; Paolo Bonanni; Carlo Lucioni; Angela Testi; Donatella Panatto
Journal:  Hum Vaccin Immunother       Date:  2016-05-10       Impact factor: 3.452

Review 4.  Systematic Review of Invasive Meningococcal Disease: Sequelae and Quality of Life Impact on Patients and Their Caregivers.

Authors:  Kerstin J Olbrich; Dirk Müller; Sarah Schumacher; Ekkehard Beck; Kinga Meszaros; Florian Koerber
Journal:  Infect Dis Ther       Date:  2018-09-28

5.  Societal costs due to meningococcal disease: a national registry-based study.

Authors:  Nina Gustafsson; Sandra Elkjær Stallknecht; Mette Skovdal; Peter Bo Poulsen; Lars Østergaard
Journal:  Clinicoecon Outcomes Res       Date:  2018-10-02

6.  Outbreaks of meningococcal meningitis in non-African countries over the last 50 years: a systematic review.

Authors:  Femke van Kessel; Caroline van den Ende; Anouk M Oordt-Speets; Moe H Kyaw
Journal:  J Glob Health       Date:  2019-06       Impact factor: 4.413

7.  Healthcare Resource Utilization and Cost of Invasive Meningococcal Disease in Ontario, Canada.

Authors:  Emmanouil Rampakakis; Julie Vaillancourt; Sara Mursleen; John S Sampalis
Journal:  Pediatr Infect Dis J       Date:  2019-03       Impact factor: 2.129

8.  Clinical and economic burden of invasive meningococcal disease: Evidence from a large German claims database.

Authors:  Liping Huang; Olivia Denise Heuer; Sabrina Janßen; Dennis Häckl; Niklas Schmedt
Journal:  PLoS One       Date:  2020-01-28       Impact factor: 3.240

Review 9.  Invasive meningococcal disease in older adults in North America and Europe: is this the time for action? A review of the literature.

Authors:  Sandra Guedes; Isabelle Bertrand-Gerentes; Keith Evans; Florence Coste; Philipp Oster
Journal:  BMC Public Health       Date:  2022-02-23       Impact factor: 3.295

10.  Invasive meningococcal disease in Italy: from analysis of national data to an evidence-based vaccination strategy.

Authors:  S Igidbashian; L Bertizzolo; A Tognetto; C Azzari; P Bonanni; P Castiglia; M Conversano; S Esposito; G Gabutti; G Icardi; P L Lopalco; F Vitale; S Parisi; G Checcucci Lisi
Journal:  J Prev Med Hyg       Date:  2020-07-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.